Research ArticleCancer

Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer

See allHide authors and affiliations

Science Translational Medicine  18 Sep 2019:
Vol. 11, Issue 510, eaaw7999
DOI: 10.1126/scitranslmed.aaw7999

Article Information

vol. 11 no. 510

PubMed: 
Print ISSN: 
Online ISSN: 
History: 
  • Received for publication February 1, 2019
  • Accepted for publication August 9, 2019
  • .

Author Information

  1. Miriam Molina-Arcas1,2,
  2. Christopher Moore1,
  3. Sareena Rana1,2,
  4. Febe van Maldegem1,
  5. Edurne Mugarza1,
  6. Pablo Romero-Clavijo1,
  7. Eleanor Herbert3,4,
  8. Stuart Horswell5,
  9. Lian-Sheng Li6,
  10. Matthew R. Janes6,
  11. David C. Hancock1 and
  12. Julian Downward1,2,*
  1. 1Oncogene Biology, Francis Crick Institute, London NW1 1AT, UK.
  2. 2Lung Cancer Group, Institute of Cancer Research, London SW3 6JB, UK.
  3. 3Experimental Histopathology, Francis Crick Institute, London NW1 1AT, UK.
  4. 4Royal Veterinary College, Hatfield AL9 7TA, UK.
  5. 5Computational Biology Laboratories, Francis Crick Institute, London NW1 1AT, UK.
  6. 6Wellspring Biosciences, San Diego, CA 92121, USA.
  1. *Corresponding author. Email: julian.downward{at}crick.ac.uk

Altmetric

Article usage

Article usage: September 2019 to January 2021

AbstractFullPdf
Sep 201944801530780
Oct 2019901480370
Nov 2019761305192
Dec 201992012697
Jan 2020881191116
Feb 202080713697
Mar 2020506140107
Apr 202026111576
May 20201648159
Jun 20201517847
Jul 20201317945
Aug 20201307644
Sep 202010722089
Oct 20204235145
Nov 20206205117
Dec 2020522984
Jan 2021210648

Stay Connected to Science Translational Medicine

Navigate This Article